OPTION-EMEANCT07349121
OPTION-EMEA Clinical Trial
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 8 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 5 → 11 locations
- Notable Eligibility criteria expanded, about 22 words
- Minor Site details revised at 1 of 5 sitesv10
- Minor Study sites: 3 to 5v9
- Notable Recruitment opened
- Study completion pushed from Dec 2028 to Dec 2029
- Study sites: 2 to 3
- Start date changed from estimate of May 2026 to Jun 18, 2026
Show 2 earlier versionsHide 2 earlier versions
- Minor Start date: Apr 2026 to May 2026v5
- Minor Study sites: 0 to 2v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Primary Safety Endpoint (PSE): Device or Procedure Related Serious Adverse Events
Timeframe: 30 days following the index procedure.
Primary Efficacy Endpoint (PEE): Acute Treatment Success
Timeframe: Through 30 days
Arms and interventions
Single arm studyOther
Subjects who meet eligibility criteria will undergo AF ablation and left atrial appendage closure using the FARAPULSE PFA system and WATCHMAN FLX Pro or WATCHMAN FLX during one interventional case.
Devices: Concomitant pulsed field ablation (PFA) and left atrial appendage closure (LAAC) during one interventional case
Procedures: Concomitant Pulsed Field Ablation and Left Atrial Appendage Closure
Sites
11 sites in 5 countries
France 3, Spain 3, Belgium 2, Italy 2, Croatia 1